EXECUTIVE TEAM Patrick Soon-Shiong, M.D., FRCS (C), FACS Chairman of the Board of Directors and Chief Executive Officer Bob Petrou Chief Financial Officer BOARD OF DIRECTORS Ron Louks Chief Operating Officer Patrick Soon-Shiong, M.D., FRCS (C), FACS Chairman of the Board of Directors and Chief Executive Officer of NantHealth, Inc. Michael S. Sitrick Chairman and Chief Executive Officer of Sitrick Group LLC Kirk K. Calhoun Former Partner at Ernst & Young LLP Michael Blaszyk Operating Partner at Beecken Petty O'Keefe & Company Deanna Wise SVP and Chief Information Officer of Banner Health CORPORATE HEADQUARTERS NantHealth, Inc. 5'8 &HQWHU 'ULYH 6XLWH 0RUULVYLOOH 1& ( ) - www.nanthealth.com ANNUAL MEETING OF STOCKHOLDERS 7KXUVday, June , 202 30 (DVWHUQ live via webcast at www.proxydocs.com/NH COMMON STO CK LISTING Nasdaq Global Select Market Ticker Symbol: NH INVESTOR RELATIONS NantHealth, Inc. Investor Relations 5'8 &HQWHU 'ULYH 6XLWH 0RUULVYLOOH 1& ir@nanthealth.com TRANSFER AGENT For questions regarding your account, changes of address or the consolidation of accounts, please contact the NantHealth’s transfer agent: American Stock Transfer & Trust Company, LLC 6201 15th Avenue Brooklyn, New York 11219 (800) 937-5449 help@astfinancial.com INDEPENDENT AUDITORS Ernst & Young LLP Los Angeles, California LEGAL COUNSEL Wilson Sonsini Goodrich & Rosati, P.C. San Diego, California This annual report contains forward-looking statements within the meaning of the United States securities laws. Such forward-looking statements are subject to risks and uncertainties that could cause NantHealth’s actual results to differ materially from those indicated by these forward-looking statements. Risks and uncertainties include, but are not limited to: the structural change in the market for healthcare in the United States, including uncertainty in the healthcare regulatory framework and regulatory developments in the United States and foreign countries; any impact of the COVID-19 pandemic, or responses to the pandemic, on our operations or personnel, or on commercial activity or demand across our and our customers’ businesses; physician, payer and pharmaceutical business needs for clinical decision support, payer/provider collaboration and data analytics solutions and any perceived advantage of our solutions over those of our competitors; our ability to increase the commercial success and to accelerate commercial growth of our clinical decision support, payer/provider collaboration, network monitoring and management, and data analytics solutions and our other products and services; our plans or ability to develop, implement and commercialize a cloud/SaaS-based version of our network monitoring and management solutions; our ability to effectively implement, offer and manage delegated entity services to health plans in a compliant and timely manner in connection with our decision support solutions; our ability to effectively manage our growth, including the rate and degree of market acceptance of our solutions; our ability to offer new and innovative products and services, including new features and functionality for our existing products and services; our ability to attract new partners and customers and our ability to retain or renew contracts with partners and customers; our ability to estimate the size of our target market; our ability to maintain and enhance our reputation and brand recognition; consolidation in the healthcare industry; competition which could limit our ability to maintain or expand market share within our industry; restrictions and penalties as a result of privacy and data protection laws; our use of “open source” software; our ability to use, disclose, de-identify or license data and to integrate third-party technologies; data loss or corruption due to failures or errors in our systems and service disruptions at our data centers; breaches or failures of our security measures; our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our users; risks related to future acquisition opportunities; the requirements of being a public company; our ability to attract and retain key personnel; our ability to obtain and maintain intellectual property protection for our solutions and not infringe upon the intellectual property of others; our financial performance expectations, including our expectations regarding our revenue, cost of revenue, gross profit or gross margin, operating expenses, including changes in research and development, sales and marketing and general and administrative expenses, and our ability to achieve and maintain future profitability; and our expectations regarding our ability to comply with Nasdaq continued listing standards. NantHealth undertakes no obligation to update any NOTE ON FORWARD LOOKING STATEMENTS forward-looking statements in light of new information or future events, except as otherwise required by law. Information on the risks and uncertainties that could affect NantHealth’s results is included in the Annual Report on Form 10-K included herewith.
RkJQdWJsaXNoZXIy NTIzOTM0